Abstract: While being well known that the diagnosis of many genetic disorders relies on a combination of clinical suspicion and confirmatory genetic testing, not rarely, however, genetic testing needs much perseverance and cunning strategies to identify the causative mutation(s).
Introduction
Mucolipidosis type III (ML III alpha/beta or ML III gamma, OMIM: 252600 and 252605, respectively) is a rare autosomal recessive disorder caused by deficiency of the (UDP)-N-acetylglucosamine: lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (termed GlcNAc-1-phosphotransferase; EC 2.7.8.17). GlcNAc-1-phosphotransferase is a Golgi-resident 540-kDa hexameric transmembrane enzyme composed by three subunits, α 2 β 2 γ 2 , which catalyzes a crucial step in the formation of the mannose 6-phosphate (M6P) recognition marker that is responsible for the correct targeting of newly synthesized lysosomal enzymes from the Golgi to the lysosomal compartment [1] . The enzyme's polypeptide chains are coded by two genes: GNPTAB and GNPTG, which encode for the α/β-subunits and the γ-subunit, respectively. While mutations in both genes may cause ML III, alterations in the GNPTAB gene can also give rise to the more severe form ML II (ML II alpha/beta; OMIM: 252500) [2] [3] [4] . The GNPTAB gene, which contains 21 exons and spans 85 kb on chromosome 12q23.3, encodes an α/β-subunit precursor of 1256 amino acids with a predicted molecular mass of 144 kDa. Proteolytic processing of the α/β-precursor by the site-1 protease generates the α-and β-subunits, whose individualization is a prerequisite for the catalytic activity of the GlcNAc-1-phosphotransferase enzymatic complex [5] . Mutations that severely affect the α/β-subunit activity and/or the complex structure in such a way that its function is abolished result in the severe ML II alpha/beta disease [6, 7] , whereas mutations leading to the formation of a protein with residual phosphotransferase activity are associated to the milder form of the disorder. MLs are devastating diseases with an extremely high morbidity rate, a life expectancy that usually does not surpass the first decade of life for the severe ML II form and, unfortunately, with no therapy available at the moment. Actually, for families at risk (i.e. with confirmed genetic diagnosis) a meaningful help to cope with the disorder is to benefit from appropriate genetic counseling, promoting informed choices that are open by the possibility of screening fetuses whenever the causative mutations are known. Thus, the identification of genetic defects underlying ML III is a challenge with important medical implications.
Here we report the thorny molecular characterization of one ML III alpha/beta patient, who was a compound heterozygous for two distinct mutations in the GNPTAB gene.
Case presentation
The patient was diagnosed at 3 years of age. Biochemical studies confirmed an impairment of the GlcNAc-1-phosphotransferase through the demonstration that the activities of several lysosomal enzymes were increased in the serum and decreased in cultured fibroblasts. β-glucocerebrosidase activity was used as a reference since this enzyme is transported to the lysosomes in a M6P-independent fashion. Biological samples of the patient were obtained under parents' informed consent and all procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration.
Genomic and cDNA analysis
GNPTAB and GNPTG genomic and cDNA analyses were performed with specific primers according to previously reported conditions [8] .
Cycloheximide treatment of control and patient fibroblasts
To perform nonsense-mediated mRNA decay (NMD) inhibition assays, patient fibroblast cell lines were cultured in the presence of two different concentrations of cycloheximide (1 and 2 mg/mL) for 3 h. Total RNA was isolated, cDNA synthesized and GNPTAB cDNA fragments amplified and sequenced.
Discussion
In order to search for the molecular defect(s) underlying the GlcNac-1-phosphotransferase impairment in the patient, cDNA analysis of the GNPTAB transcript was performed and the missense mutation c.1196C>T(p.S399F) [8] was identified in heterozygosity. No other alterations were detected through repeated amplification of the GNPTAB cDNA, even though both the patient clinical presentation and the biochemical results were incoherent with the expectations for a carrier individual. The discrepancy prompted further investigation with gDNA, carrying out amplification and sequencing of all 21 exons of GNPTAB and their intronic flanking regions as well of both the 5′ and 3′ untranslated regions of the gene. Once again, no other mutations were detected apart from the missense c.1196C>T(p.S399F) already identified in the cDNA.
Knowing that GNPTAB codes for only two (α-and β-) of the three subunits that form the active GlcNac-1-phosphotransferase, we questioned whether any mutation(s) in the GNPTG gene, which codes for the third subunit (γ-), could be contributing to the patient's phenotype, and so a gDNA analysis of all GNPTG exons and corresponding flanking regions was performed, failing also to reveal any pathogenic alteration.
Next, attention was again focused on the GNPTAB gene, exploring the presence of any mutation generating a mRNA transcript that could be a candidate for NMD. In order to test whether the NMD process was masking/ degrading any mutant transcript, patient's fibroblasts were cultured with cicloheximide in a final concentration of 2 mg/mL for 3 h to inhibit the NMD process, rescuing eventual aberrant transcripts. After doing so, total RNA was isolated from the pelleted cells and the respective cDNA synthesized, providing an alternative approach to analyse the GNPTAB transcript. Examining the sequence of the six fragments, we successfully detected a second heterozygous mutation, c.3503_3504delTC, which was a relatively common deletion on exon 19 ( Figure 1B and  1C) . This was rather surprising, because the alteration escaped previous detection at the gDNA level (data not shown), despite the methodology to screen for it was very well-implemented in our laboratory, as demonstrated in previous works where we reported that the deletion was the most common mutation among Portuguese patients [8, 9] . One possible explanation to the failure to detect the mutation in this patient could rely in the cis presence in the allele carrying the deletion of an additional variation in any of the primer annealing regions, leading to the preferential amplification of the other allele when exon 19 and its boundaries were submitted to PCR. Accordingly, the next step was to design a second pair of primers surrounding the target exon but in an outer region relatively to the initially used primers' pair, perform PCR amplification in optimal conditions (primer sequences and PCR conditions available on request), and at last we were able to detect the deletion c.3503_3504delTC in heterozygosity ( Figure 1A) . Furthermore, one polymorphism was identified in the annealing region of the former reverse primer, confirming sequence variation as the cause of the observed allele-specific dropout. When the patient's parents were analyzed, we found out that the patient's mother was the carrier of the c.3503_3504delTC mutation, which in fact was detected with the two different pairs of primers, showing that the polymorphism was not inherited in cis with the mutant allele, but instead it was likely a de novo variant.
Having elucidated this particular case of allele-dropout, is worth mentioning that besides sequence variation, other factors do exist accounting for the amplification success, that might also cause differential amplification of two alleles. It has been demonstrated, for example, that differential DNA methylation can affect PCR, resulting in allele dropout due to preferential amplification of unmethylated alleles [10] . Secondary structures in the template DNA may also contribute to compromise the amplification efficiency [11] .
Finally, and regarding cDNA characterization as a routine procedure in molecular diagnoses, as long as that persists much attention should be paid in the NMD process and its implications in the ability to pinpoint causative mutations. As NMD is a cellular quality control mechanism that recognizes abnormal mRNAs harboring premature termination codons (PTC) and degrades them, mutations that do trigger such mechanism may likely fail detection through cDNA analysis alone, thereby implying that gDNA screening should be always considered when cDNA provides negative or unsatisfactory results. Another case involving a ML III alpha/beta patient, who was studied in our lab can illustrate how NMD may lead to misdiagnosis. The patient was diagnosed at the age of 7 years presenting with polydistrophic dwarfism. Enzymatic assays revealed impaired activity of the GlcNAc-1-phosphotransferase. Like in the former patient, screening of GNPTAB in cDNA only enabled the identification of one missense mutation in heretozygozity, c.1208 (p.I403T) [9] . Yet, when screening the gDNA, a second pathogenic alteration was identified on exon 13: the nonsense mutation c.1999G>T(p.E667*) (data not shown). When the cultured fibroblasts from the patient were incubated with cicloheximide, in the novel cDNA sample synthesized using the extracted total RNA as template it was possible to detect the nonsense mutation (data not shown). Once again, NMD was masking the patient's genotype when inferred from cDNA without previous inhibition of NMD.
An important observation about the two NMD-triggering mutations here scrutinized, was their clear identification before in other patients in whom it was screened cDNAs obtained from non-cicloheximide-treated fibroblasts [9] , which probably reflects the fact that NMD is not a mechanism 100% efficient. But yet in general, and as the two patients here studied demonstrate, NMD substantially accounts to degrade translationally abnormal mRNAs, implying therefore that the process should always be kept in mind when analysing cDNA sequences.
In conclusion, these two instances of tricky molecular diagnoses highlight the importance of relying in complementary genetic approaches to identify pathogenic mutations, in order to reduce the rate of genetically undiagnosed cases and consequent dramatic implications especially for prenatal testing, whose value in the clinical setting goes hand in hand with quick and accurate results.
